AHA Urges CMS to Consider 340B When Implementing MDPNP, PhRMA Warns Against ‘Price Setting’

AHA Urges CMS to Consider 340B When Implementing MDPNP, PhRMA Warns Against ‘Price Setting’

A key national hospital trade group recently called on CMS leaders to “avoid unintended consequences” affecting the 340B program—and the patients that AHA urged CMS to “avoid unintended consequences” affecting the 340B program—and the patients that benefit from it—as the agency continues to implement the Medicare Drug Price Negotiation Program (MDPNP).